In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living ...

Primary esophageal epithelial cells (keratinocytes) from normal human esophagus were established as described previously. 6 Fetal esophageal fibroblasts (FEF) were isolated as previously described ...

San Diego-based iBio, an AI-driven innovator of precision antibody therapies, has announced a licensing agreement with ...

iBio announces licensing agreement with AstralBio for a novel antibody targeting Activin E, potentially aiding weight loss and cardiometabolic health. Bio, Inc. has announced a licensing agreement ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

type I receptor in more than 95% of FOP patients that aberrantly activate BMP signaling by Activin A, a TGF-β ligand. This heterotopic ossification (HO) is typically associated with flare-ups ...

An update from Ibio ( ($IBIO) ) is now available. On April 21, 2025, iBio, Inc. entered into an exclusive licensing agreement with AstralBio, Inc.

The goal of the study was to confirm whether modified NK cells had the capacity to overcome the negative effects of the TGF-β and Activin A molecules in preclinical models of HER2-positive breast ...

Serum cancer antigen 125, creatine kinase and activin A levels have been studied as possible predictors of pregnancy outcome. However, no single factor has yet been identified to predict the ...